Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Study to understand how incretin mimetics affect cancer risk and attract experts to investigate these mechanisms, aiming to differentiate impacts on cancer risk from other health outcomes like weight loss or diabetes.
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Resubmissions) | January 7, 2027 (Closing date)
Funding Amounts: No budget limit; requests must reflect project needs; maximum project period of 5 years
Summary: Supports mechanistic animal and human studies examining how incretin mimetics influence cancer risk.
Key Information: Well-developed projects with preliminary data are required; entirely in vitro and primarily epidemiological projects are nonresponsive.
Description
The National Cancer Institute (NCI), part of NIH, supports investigator-initiated research on mechanisms through which incretin mimetics influence cancer risk. This R01 opportunity emphasizes GLP-1 and dual GLP-1/GIP-1 receptor agonists, whose reported effects on thyroid, prostate, and other cancers warrant mechanistic investigation. It also seeks to bring scientists studying these agents in other diseases into cancer biology.
Projects may examine immune, metabolic, hormonal, cytokine, or other signaling changes; cancer-specific effects; differences among population groups; or dose-related and off-target mechanisms. The focus is biological mechanisms affecting cancer prevention or promotion, rather than short-term weight loss or diabetes outcomes. Animal and human studies are supported, and clinical trials are optional. This opportunity is intended for well-developed projects supported by preliminary data.
